EGFR and neoplasm: One of the possible explanations for the presently observed supra-additive anti-tumour activity may lie in an optimal ‘vertical blockade’ of VEGF pathway not obtained by either agent alone bearing in mind that EGFR targeting leads to inhibition of VEGF tumour secretion (Byers and Heymach, 2007).